ScreenerHero
APSAptose Biosciences Inc.
TSX · CA · Healthcare · Biotechnology · aptose.com
2.400CAD0.00%Mkt Cap: 4.46M $P/E: —

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kin…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
HeadlineSourceTime
Older
Aptose Biosciences: Q3 Earnings Snapshot

TORONTO (AP) — Aptose Biosciences Inc. APTOF) on Thursday reported a loss of $5.1 million in its third quarter. On a per-share basis, the Toronto-based company said it had a loss of $2.01.

AAssociated Press Finance
Aptose Biosciences Reports Promising Early Results from Tuscany AML Trial of Tuspetinib Combo Therapy

Aptose Biosciences (APS.TO) said Thursday that data from the ongoing Tuscany trial of tuspetinib in

MMT Newswires
Aptose Secures US$11.9M Loan Extension to Advance Tuspetinib AML Trial

Aptose Biosciences (APS.TO) Monday said it has entered into a US$11.9 million loan amended facility

MMT Newswires
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients

Aptose Biosciences (APS.TO) on Monday said the latest data update from the Phase 1/2 Tuscany trial i

MMT Newswires